GET DAILY SIGNALSCoherus Oncology (CHRS): Is a +1,030% Rally to the $7.25 Target Feasible?
Key Takeaways
- The $7.25 central target is the average of four analyst price targets from H.C. Wainwright ($7), Maxim Group ($4), Guggenheim ($8), and Oppenheimer ($10), spanning a range of $4 to $10.
- At a recent price near $0.64, reaching $7.25 would require an increase of roughly 1,030%, an unusually large move even for small-cap biotech.
- Targets rest primarily on probability-adjusted models for the clinical pipeline, including tagmokitug and casdozokitug, along with Loqtorzi commercialization rather than current fundamentals.
- Key support comes from the approved PD-1 therapy Loqtorzi and early positive signals for tagmokitug in esophageal cancer.
- Major risks include a going-concern warning, cash runway under 12 months, decelerating Loqtorzi sales, and potential dilution or reverse split.
- Investors can follow major news, price moves, forecasts, and earnings updates on dedicated pages for CHRS.
Understanding the Analyst Consensus
The $7.25 figure comes from four recent attributed targets. H.C. Wainwright started coverage with a Buy rating and $7 target in late October 2026. Maxim Group kept a Buy at $4, Oppenheimer held at $10, and Guggenheim trimmed from an earlier $12 down to $8 after third-quarter results. The average of these four is $7.25, with the spread from $4 to $10 highlighting how much depends on clinical and financing outcomes. I also checked this using Tickeron’s AI Screener to see how CHRS compares to peers in the space.
Current Price Action and the Scale of the Move
CHRS closed near $0.64 on November 10, 2026, after dropping more than 20% in one session on third-quarter results. The stock is down about 49% over the past year and 55% year to date, with a 52-week range of $0.60 to $2.62. Closing the gap to $7.25 would require an increase of approximately 1,030%, which would need both a re-rating and meaningful progress on liquidity and pipeline value.
Factors That Could Support Higher Levels
- Loqtorzi remains the only FDA-approved treatment for recurrent or metastatic nasopharyngeal carcinoma and posted 25% year-over-year sales growth in the third quarter.
- Tagmokitug delivered a 33.3% confirmed response rate in second-line esophageal cancer, with median progression-free survival of 5.5 months against a chemotherapy benchmark near 10%.
- Two potential $37.5 million Udenyca divestiture milestones could provide additional cash if resolved positively.
- A 30% workforce reduction and a narrower pipeline have lowered the quarterly revenue threshold needed for self-sufficiency.
Key Risks That Could Keep the Stock Pressured
- The company included going-concern language, with cash and investments of roughly $83.6 million and a runway of less than 12 months.
- Loqtorzi growth slowed, rising only about 3% sequentially and missing the 10–15% quarterly target management had set.
- Full-year 2026 guidance for Loqtorzi was reduced to $54–57 million from $57–62 million, and the company missed consensus revenue.
- An ATM facility and convertible-debt overhang point to dilution risk, while the sub-$1 price raises the chance of a reverse split.
Technical Picture and Levels to Watch
CHRS sits below both its 50-day moving average near $1.16 and 200-day moving average near $1.52, trading close to the $0.60 52-week low. The $1.00 mark is a key psychological level, while $0.85–$0.90 represents near-term resistance. Any sustained move toward multi-dollar targets would first require reclaiming and holding well above current prices.
Time Horizon and Items to Monitor
Analyst targets generally reflect a roughly 12-month view, though that can shift with acute financing concerns. I’m watching clinical data for tagmokitug and casdozokitug, any resolution on the Udenyca earn-out, potential partnerships or financings, Loqtorzi prescription trends, and the next quarterly report.
Using AI Daily Buy/Sell Signals in Practice
Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions and technical behavior. For a volatile name like CHRS, these signals offer an additional data layer that can help monitor positions and spot trend shifts more efficiently alongside other research.
Final Assessment
Whether CHRS can reach $7.25 hinges more on resolving liquidity issues and advancing the pipeline than on near-term earnings. The $7.25 average of four targets from $4 to $10 implies a move of roughly 1,030% from current levels, reflecting probability-weighted valuations that the market is discounting heavily. Supportive elements include an approved and growing product plus encouraging early data, while going-concern risk, slower Loqtorzi growth, and dilution pressure remain the main hurdles. Investors should track cash runway, clinical readouts, and financing developments, keeping in mind that the target is an analyst estimate rather than a guaranteed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CHRS's Stochastic Oscillator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Oscillator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement